-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease (PD) is a complex disorder with a wide variety of symptoms that negatively affects patients' quality of life (QoL) and independence of daily living (ADL)
Quality of Life
It has even been suggested that PD is not just a dopaminergic motor disorder, but a central and peripheral nervous system dysfunction driven by multiple neurotransmitter pathways, and should be considered a syndrome rather than a disease
Previous studies have shown that TD variants have slower progression and less deterioration in terms of QoL, and several serum markers have been identified to be associated with TD
Recently, Luo et al.
While some studies have not actually found significant differences in symptoms and dopaminergic innervation between TD and PIGD patients after a period of follow-up, it is important to note the clinical outcomes of patients who switch from the TD subtype to the PIGD subtype during disease progression poor
511 patients (62.
The significance of this study lies in the discovery; the MP of PD can vary over time
The MP of a PD can vary over time
Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up.
Leave a Comment here